Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Harald Stenmark<br>Acting Inst. Head
Harald Stenmark
Acting Inst. Head

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
2017 so far  
 2016 235  15
2015 221 21
2014 174 25

Annual report 2015 (pdf format)


Latest news

Tone Rustøen "Researcher of the Month" for July

Tone Rustøen
Tone Rustøen

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has appointed Tone Rustøen from the Nursing Research Group at the Division of Emergencies and Critical Care at Oslo University Hospital as "Researcher of the month" for the month of July.


Call for applications 2018

Annuncement of research funding from South-East Norway regional health authority for 2018


The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2018.

The total funding available for this call is approximately 100 million Norwegian kroner.

Application deadline is Tuesday, September 5th 2017 kl. 16:00.


OUH scientists involved in sequencing study of osteosarcoma that has identified mutations in IGF signalling genes

From left: Zaikova, Bjerkehagen and Myklebost
From left: Zaikova, Bjerkehagen and Myklebost

A portion of bone cancers may respond to existing insulin-like growth factor 1 receptor inhibitors because they carry mutations in IGF signaling genes, a study recently published in Nature Communications suggests. The sarcoma team at the Norwegian Radium Hospital at Oslo University Hospital was represented in this study by Bodil Bjerkehagen, the sarcoma reference pathologist, Olga Zaikova, on behalf of the orthopedists, and Ola Myklebost, PI in the ICGC Bone Cancer Project. This study is a side branch from their previous participation in the European Network of Excellence on Bone Tumours, and is carried out by the International Cancer Genomics Consortium at the Sanger Centre in Hinxton outside Cambridge.


Håvard Danielsen appointed "Scientist of the Month" by "Helse Sør-Øst" for June 2017

Håvard Danielsen
Håvard Danielsen

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".

For the month of June 2017, this honour went to professor Håvard Danielsen, head of the Institute for Cancer Genetics and Informatics at OUH.


Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2016

Award winners during the ceremony (photo Marethe Falch)
Award winners during the ceremony (photo Marethe Falch)

Six research groups were awarded for their excellent papers published during the second half-year of 2016 during a ceremony June 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.


Øyvind S. Bruland appointed "Innovator of the Month" by Helse Sør-Øst

Øyvind S. Bruland
Øyvind S. Bruland

Professor Øyvind Sverre Bruland, senior consultant oncologist at the Department of Oncology at the Division of Cancer Medicine, has been interviewed in connection with being appointed "Innovator of the Month" by South-Eastern Norway Regional Health Authority (Helse Sør-Øst). His clinical experience and research are mainly devoted to primary bone and soft tissue cancers (sarcomas) and skeletal metastases from prostate cancer and breast cancer. In particular, targeted radionuclide therapy, e.g. Alpharadin (Algeta), based on Radium-223, is currently at center stage.